Table 2 Dose and schedule for the evaluation of anti-Nodal antibody WS65 and the BRAFi dabrafenib in the A375SM-L1 model of melanoma metastasis to the lung
From: Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells
Group | Xenograft | Drug given | Dose | Frequency of treatment | Route |
|---|---|---|---|---|---|
Group 1 (N=5) | A375SM-L1 | Non-specific (NS-IgG) antibody | 50 μg/20 g mouse | Once per week | IP |
Group 2 (N=4) | A375SM-L1 | Vehicle control for dabrafenib | Similar volume as treated with dabrafenib per 20 g mouse | M,W,F | Oral gavage |
Group 3 (N=5) | A375SM-L1 | WS65 | 50 μg/20 g mouse | Once per week | IP |
Group 4 (N=4) | A375SM-L1 | Dabrafenib | 3 mg/kg | M,W,F | Oral gavage |
Group 5 (N=4) | A375SM-L1 | WS65 and dabrafenib | 50 μg/mouse and 3 mg/kg | Once per week/and M,W,F | IP/and oral gavage |
